Clinical trials: Ribavirin
Hepatitis C, Chronic
A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)
This multicenter, randomized, double-blind, parallel group study will evaluate the safety and efficacy of the combination RO5024048 and ritonavir-boosted danoprevir with and without Copegus (ribavirin) in patients with chronic…
- Trial name
- NCT01278134
- Testing
- RO5024048, danoprevir, peginterferon alfa-2a [Pegasys]
- Where
- 32 sites in United States, France and 2 more
- Volunteers
- 170 people
- Sponsor
- Hoffmann-La Roche
Liver Cirrhosis, Experimental
Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
To evaluate: 1. the impact of combined antiviral therapy (Peginterferon plus ribavirin) on natural history of patients affected with HCV decompensated cirrhosis, after sustained virological response. A controlled study. 2.
- Trial name
- NCT00301509
- Testing
- peginterferon and ribavirin
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Hepatitis C
Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant
The aim of the study is to assess whether patients with recurrent hepatitis C after liver transplantation will benefit from a treatment with ribavirin/PEG-IFN-alpha combined treatment for 48 weeks.
- Trial name
- NCT00466219
- Testing
- Ribavirin, Pegylated interferon alpha2a
- Volunteers
- 25 people
- Sponsor
- University Hospital, Geneva
Chronic Hepatitis C Virus
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) administered for 8 or 12 weeks in treatment-naive…
- Trial name
- NCT01851330
- Testing
- LDV/SOF, RBV
- Where
- 52 sites in United States
- Volunteers
- 647 people
- Sponsor
- Gilead Sciences
Hepatitis C, HIV Infections
Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens
This trial will assess the sustained virologic response to treatment with peginterferon alfa-2a combined with high-dose ribavirin in human immunodeficiency virus (HIV)-infected patients with hepatitis C virus (HCV) genotype 1 or…
- Trial name
- NCT00470210
- Testing
- Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week, Ribavirin (Copegus®) 1600 mg/day, Epoetin β (450 UI/kg/week)
- Where
- 2 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Germans Trias i Pujol Hospital
Hepatitis C
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
The hypothesis of this study is that pegylated interferon would cause cognitive deficits and mood changes in hepatitis C (HCV) positive subjects.
- Trial name
- NCT00136214
- Testing
- MR brain and neuropsychiatric tests
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Beth Israel Deaconess Medical Center
Liver Cirrhosis, Chronic Hepatitis C
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)
This study evaluated the clinical response of the efficacy and safety of the combination therapy of peginterferon alfa-2a and ribavirin, compared with an antiviral treatment-free group in CHC patients with compensated LC.
- Trial name
- NCT00304551
- Testing
- peginterferon alfa-2a 180μg, peginterferon alfa-2a 90μg, ribavirin
- Where
- 8 sites in Japan
- Volunteers
- 180 people
- Sponsor
- Chugai Pharmaceutical
Hepatitis C Virus
Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients
Genotype 1: Participants with genotype 1 hepatitis C (HCV) infection were randomized to receive sofosbuvir (GS-7977; PSI-7977) 200 mg or 400 mg, or matching placebo, plus pegylated interferon alfa 2a (PEG) and ribavirin (RBV) for…
- Trial name
- NCT01188772
- Testing
- Sofosbuvir, PEG, RBV
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 147 people
- Sponsor
- Gilead Sciences
HIV Infections, Hepatitis C
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs…
- Trial name
- NCT01482767
- Testing
- Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC)
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 262 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic, Hepatitis C
Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)
Adherence to the prescribed treatment regimen with PegIntron and Rebetol affects the chance of achieving a sustained virologic response in patients with hepatitis C.
- Trial name
- NCT00705107
- Testing
- PegIntron pen (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 267 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C, Fibrosis
Combination Drug Therapy for Patients With Hepatitis C
Hepatitis C is a major cause of liver disease in the United States and leads to cirrhosis of the liver in approximately one-third of patients some of whom will ultimately suffer from liver failure or liver cancer.
- Conditions
- Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
- Trial name
- NCT00001729
- Testing
- Ribavirin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C Virus Infection
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection
The primary objectives of this study are to compare the efficacy of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks with that of sofosbuvir (SOF) + ribavirin (RBV) for 24 weeks and to…
- Trial name
- ASTRAL-3 (NCT02201953)
- Testing
- SOF/VEL, SOF, RBV
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 558 people
- Sponsor
- Gilead Sciences
Hepatitis C, Relapse
Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse
The primary goal of hepatitis C virus (HCV) Direct Acting Antivirals (DAAs) is to achieve undetectable HCV RNA in the blood. A response that should be maintained for at least 12 weeks from completion of therapy.
- Conditions
- Hepatitis C, Relapse, Antivirals
- Trial name
- NCT04662138
- Testing
- directly acting antivirals
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Hemorrhagic Fever
Treatment of Hemorrhagic Fever With Ribavirin
Multisite protocol to provide IV Ribavirin treatment to patients with probable or suspected case of Hemorrhagic Fever with Renal Syndrome (HFRS)
- Trial name
- NCT04283513
- Testing
- Virazole
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Chronic Hepatitis C
Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C
This study is designed to provide a preliminary assessment of the safety and effectiveness of the combination of PPI-668, BI 207127 and faldaprevir, with or without ribavirin, in the treatment of chronic hepatitis C virus…
- Trial name
- NCT01859962
- Testing
- PPI-668, BI 207127 Dose 1, BI 207127 Dose 2
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Presidio Pharmaceuticals, Inc.
Hepatitis C, Hepatitis C, Chronic
Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin
Chronic hepatitis C infection is one of the leading causes of chronic liver disease in the United States. Approximately one-third of patients with hepatitis C infection develop cirrhosis of the liver, which can lead to liver…
- Trial name
- NCT00039962
- Testing
- thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- SciClone Pharmaceuticals
Liver Cirrhoses, Chronic Hepatitis c
Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin
Use of Ribavirin could affect hematologic profile of the patients negatively. With advent of new antiviral therapy, the preexisting hematologic changes may alter or corrected after treatment.
- Conditions
- Liver Cirrhoses, Chronic Hepatitis c, Directly Acting Antivirals
- Trial name
- NCT03283176
- Testing
- Vitamin B12 and Folic Acid
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Hepatitis C, Drug Use
DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)
The study aims to assess the effectiveness of a model of hepatitis C screening and integrated care, targeting people who inject drugs (PWIDs) in Hai Phong, Vietnam.
- Conditions
- Hepatitis C, Drug Use, Viral Hepatitis C
- Trial name
- DRIVE-C (NCT03537196)
- Testing
- Sofosbuvir 400 mg and Daclatasvir 60 mg, Sofosbuvir 400 mg and Daclatasvir 90 mg, Ribavirin
- Where
- 2 sites in Vietnam
- Volunteers
- 979 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Infection
Orange Juice Consumption in Patients With Hepatitis C
This study aimed to verify whether orange juice, source of citrus flavonoids and vitamin C, may contribute to the treatment of patients with chronic hepatitis C.
- Trial name
- NCT03026569
- Testing
- Orange juice (500 mL/d)
- Where
- Brazil
- Volunteers
- 43 people
- Sponsor
- São Paulo State University
Chronic Hepatitis C Infection, Hepatitis C
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study is to evaluate the antiviral activity, safety, and pharmacokinetics of ABT-450 with ritonavir (ABT-450/r) dosed in combination with ABT-333 (also known as dasabuvir) and ribavirin (RBV) in…
- Conditions
- Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus
- Trial name
- NCT01306617
- Testing
- ABT-450, ABT-333, ribavirin
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- AbbVie (prior sponsor, Abbott)